XFOR - X4 Pharmaceuticals GAAP EPS of -$0.01 beats by $0.14
2023-11-09 06:06:07 ET
More on X4 Pharmaceuticals
- X4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger Market
- X4 Pharmaceuticals says CEO Paula Ragan sells 239.4K shares
- X4 shares jump as FDA accepts priority review of pediatric WHIM drug
- Seeking Alpha’s Quant Rating on X4 Pharmaceuticals
- Historical earnings data for X4 Pharmaceuticals
For further details see:
X4 Pharmaceuticals GAAP EPS of -$0.01 beats by $0.14